从2026年开始,《医疗保健计划》将涵盖针对患有肥胖健康问题的老年人和残疾人的减重药物。 Starting in 2026, Medicare will cover weight-loss drugs for seniors and disabled people with obesity-related health issues.

从2026年开始,医疗保险将为27或更高BMI和相关健康状况的受益人提供FDA批准的减肥药物,如西马格卢提德和提泽帕提德,这标志着联邦对肥胖作为慢性疾病的覆盖面的重大转变. Starting in 2026, Medicare will cover FDA-approved weight-loss drugs like semaglutide and tirzepatide for beneficiaries with a BMI of 27 or higher and related health conditions, marking a major shift in federal coverage of obesity as a chronic disease. 这一变化是由多年的宣传推动的,目的是改善数以百万计的老年人和残疾美国人获得服务的机会,这些人以前面临高昂的费用。 The change, driven by years of advocacy, aims to improve access for millions of older and disabled Americans who previously faced high costs. 预计最后规则将于2025年初制定,实施时间定于2026年1月。 Final rules are expected in early 2025, with implementation set for January 2026.